EnovisENOV +12.28%60 9-Day RSI is 54.55 as of Jul. 05, 2026. GuruFocus rates ENOV with a GF Score™ of 60/100 and a GF Value™ of $49.62 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 869 Medical Devices & Instruments companies, Enovis ranks worse than 55.81% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-05), Enovis's 9-Day RSI is 54.55.
The industry rank for Enovis's 9-Day RSI or its related term are showing as below:
ENOV's 9-Day RSI is ranked worse than 55.81% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 52.28
vs ENOV: 54.55
Enovis (NYSE:ENOV) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Enovis 9-Day RSI Related Terms
ENOV vs INSP, PRCT, AHCO: 9-Day RSI Comparison
For the Medical Devices subindustry, Enovis's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enovis 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Enovis's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Enovis's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enovis (ENOV) has a 9-Day RSI of 54.55 as of Jul. 05, 2026. According to the industry distribution chart, Enovis ranks #485 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 55.8%.
Is Enovis' 9-Day RSI too high?
Enovis' current 9-Day RSI is 54.55. The Medical Devices & Instruments industry median 9-Day RSI is 52.28. Enovis' value of 54.55 is 4.3% above this industry median. Based on the distribution chart, Enovis ranks #485 out of 869 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Enovis has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' 9-Day RSI compare to INSP and PRCT?
According to the Medical Devices & Instruments industry distribution chart, Enovis ranks #485 out of 869 companies for 9-Day RSI. This places Enovis in the lower half of its industry. The industry median 9-Day RSI is 52.28. Enovis' value of 54.55 is 4.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 52.28, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enovis's current 9-Day RSI of 54.55 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 52.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enovis's current 9-Day RSI is 54.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $49.62, compared to a current price of $22.50 — trading 54.7% below its estimated fair value. The current 9-Day RSI is 54.55 and 4.3% above the Medical Devices & Instruments industry median of 52.28. Enovis' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Enovis (ENOV), the current 9-Day RSI is 54.55 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enovis (ENOV) Overvalued in 2026?
Based on GuruFocus' analysis, Enovis stock appears to be undervalued.
The current stock price of $22.50 is trading 54.7% below its estimated GF Value™ of $49.62.
GuruFocus considers Enovis to be Possible Value Trap.
Key valuation signals for ENOV:
9-Day RSI: 54.55
GF Value™: $49.62 vs. price of $22.50 (54.7% below fair value)
Industry Position: 4.3% above the Medical Devices & Instruments median (#485 of 869)
No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
60GF Score
Get the complete analysis for ENOV
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENOV has been successfully added to your 